and Explanations

Introduction

Phase 1 clinical trials are foundational to drug development. They are rich with specialized terminology spanning pharmacokinetics, safety monitoring, statistics, and regulatory science. This glossary provides concise definitions of scientific terms and acronyms commonly used in Phase 1 trials, helping students, clinicians, and professionals build a solid understanding of early-phase research.

Glossary of Phase 1 Terms

• FIH (First-in-Human): The initial administration of a new investigational drug in human subjects, typically healthy volunteers.
• SAD (Single Ascending Dose): A trial design where individual groups receive increasing single doses to assess safety and pharmacokinetics.
• MAD (Multiple Ascending Dose): A Phase 1 trial design where subjects receive repeated dosing over time to observe accumulation, safety, and steady-state pharmacokinetics.
• PK (Pharmacokinetics): The study of how the body absorbs, distributes, metabolizes, and eliminates a drug.
• PD (Pharmacodynamics): The study of a drug’s biological and physiological effects and its mechanism of action.
• MTD (Maximum Tolerated Dose): The highest dose of a drug that does not cause unacceptable side effects.
• DLT (Dose-Limiting Toxicity): A side effect that prevents further dose escalation; defines the upper safety boundary in dose-escalation studies.
• NOAEL (No Observed Adverse Effect Level): The highest dose in animal studies at which no significant adverse effects are observed.
• MABEL (Minimum Anticipated Biological Effect Level): The lowest dose expected to cause a biological effect in humans; often used in biologics for FIH dose determination.
• RDE (Recommended Dose for Expansion): The selected dose for Phase 2 or cohort expansion, which may be below MTD based on safety or efficacy trends.
• EC50: The concentration of a drug that produces 50% of its maximal effect; commonly used in PD studies.
• Half-Life (t_1/2): The time it takes for the drug concentration in plasma to decrease by half.
• C_max: The maximum plasma concentration of a drug after administration.
• AUC (Area Under the Curve): A measure of the total drug exposure over time.
• T_max: The time it takes to reach C_max after drug administration.
• Sentinel Dosing: A safety measure in which 1–2 subjects are dosed initially and monitored before the rest of the cohort receives the drug.
• 3+3 Design: A traditional dose-escalation method in which 3 subjects are treated per cohort; if toxicities occur, more subjects are added per predefined rules.
• CRM (Continual Reassessment Method): A Bayesian model-based method to estimate MTD more efficiently during dose escalation.
• BOIN (Bayesian Optimal Interval): A dose-finding method that guides escalation based on observed toxicity probabilities.
• mTPI (Modified Toxicity Probability Interval): A statistical model to determine whether to escalate, de-escalate, or stay at the current dose level.
• Placebo-Controlled: A trial in which a control group receives an inactive substance to compare with the drug’s effects.
• Double-Blind: A study design in which neither participants nor investigators know who receives the drug or placebo.
• Randomization: Assignment of subjects to treatment or control arms using chance to reduce bias.
• Bioavailability: The proportion of an administered dose that reaches systemic circulation in an active form.
• Bioequivalence (BE): When two drug formulations have comparable bioavailability and PK profiles within predefined limits (typically 80–125% AUC and C_max).
• Biosimilarity: Demonstrating that a biologic product is highly similar to an approved reference product with no clinically meaningful differences.
• Immunogenicity: The ability of a biologic or protein-based drug to provoke an immune response in the body.
• ADA (Anti-Drug Antibody): Antibodies formed against a therapeutic drug, potentially impacting efficacy and safety.
• NAb (Neutralizing Antibody): A subset of ADAs that block the drug’s biological activity.
• CHIM (Controlled Human Infection Model): A model in which volunteers are deliberately infected with a pathogen to test vaccine or treatment efficacy in a controlled setting.
• Healthy Volunteer: A subject without the target disease enrolled in early-phase studies to assess basic drug safety and PK.
• Washout Period: Time interval required to eliminate a prior treatment’s effects before the next dose or trial participation.
• Informed Consent: A documented process ensuring participants understand study risks, procedures, and their rights before enrollment.
• DSMB (Data and Safety Monitoring Board): An independent group that reviews safety data during a trial to ensure participant protection.
• Protocol Deviation: A departure from the approved study protocol that may affect trial integrity or subject safety.
• Investigator Brochure (IB): A comprehensive document summarizing preclinical and clinical data relevant to the study drug.
• IND (Investigational New Drug): An application submitted to the FDA to begin clinical testing in humans.
• CTA (Clinical Trial Application): Regulatory submission to start human trials in the EU or other regions.

Conclusion

Understanding the language of Phase 1 trials is crucial for effective communication among researchers, sponsors, regulators, and students. These terms are not only scientific but also operational anchors in trial design and execution. Whether you’re a clinical research professional or a student exploring early-phase studies, this glossary provides a solid foundation for navigating the complex world of drug development.